Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Trading Up 4.9 %

Shares of JAGX stock opened at $5.38 on Friday. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.84 and a quick ratio of 1.36. The firm has a 50-day moving average price of $16.83 and a 200 day moving average price of $23.42. Jaguar Health has a twelve month low of $4.90 and a twelve month high of $540.00.

Institutional Trading of Jaguar Health

An institutional investor recently bought a new stake in Jaguar Health stock. Virtu Financial LLC purchased a new position in Jaguar Health, Inc. (NASDAQ:JAGX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned 0.22% of Jaguar Health as of its most recent SEC filing. 12.04% of the stock is owned by hedge funds and other institutional investors.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.